H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Carisma Therapeutics to $11 from $10 and keeps a Buy rating on the shares post the Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CARM:
- Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Carisma Therapeutics reports Q2 EPS (49c), consensus (60c)
- Carisma Therapeutics initiated with an Outperform at Evercore ISI
- Carisma announces first patient dosed in Phase I clinical trial of CT-0508
- Carisma to be added to Russell 2000, Russell 3000, and Russell Microcap
